Treatment of Primary Liver Tumors with Yttrium-90 Microspheres (TheraSphere®) in High Risk Patients: Analysis of Survival and Toxicities

Reardon, Kelli A.; McIntosh, Alyson; Shilling, A. Tanner; Hagspiel, Klaus D.; Al‐Osaimi, Abdullah; Berg, Carl L.; Caldwell, Stephen H.; Angle, Fritz; Mulder, Robert L.; Rich, Tyvin A.

doi:10.1177/153303460900800109

Cited by 11 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies considering patients with extrahepatic spread [26] or patients with deteriorated liver function (Child-Pugh C stage) [18] or patients awaiting liver transplantation [14] were excluded from the analysis.…”

Section: Resultsmentioning

confidence: 99%

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses

et al. 2016

View full text Add to dashboard Cite

Trans-arterial radioembolization (TARE) is a recognized, although not explicitly recommended, experimental therapy for unresectable hepatocellular carcinoma (HCC).A systematic literature review was performed to identify published studies on the use of TARE in intermediate and advanced stages HCC exploring the efficacy and safety of this innovative treatment.Twenty-one studies reporting data on overall survival (OS) and time to progression (TTP), were included in a meta-analysis. The pooled post-TARE OS was 63% (95% CI: 56-70%) and 27% (95% CI: 21-33%) at 1- and 3-years respectively in intermediate stage HCC, whereas OS was 37% (95% CI: 26-50%) and 13% (95% CI: 9-18%) at the same time intervals in patients with sufficient liver function (Child-Pugh A-B7) but with an advanced HCC because of the presence of portal vein thrombosis. When an intermediate and advanced case-mix was considered, OS was 58% (95% CI: 48-67%) and 17% (95% CI: 12-23%) at 1- and 3-years respectively. As for TTP, only four studies reported data: the observed progression probability was 56% (95% CI: 41-70%) and 73% (95% CI: 56-87%) at 1 and 2 years respectively. The safety analysis, focused on the risk of liver decompensation after TARE, revealed a great variability, from 0-1% to more than 36% events, influenced by the number of procedures, patient Child-Pugh stage and treatment duration.Evidence supporting the use of radioembolization in HCC is mainly based on retrospective and prospective cohort studies. Based on this evidence, until the results of the ongoing randomized trials become available, radioembolization appears to be a viable treatment option for intermediate-advanced stage HCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The beneficial role of Y on the corrosion of Mg alloy in cell culture medium was also reported [14]. Although some rare earth elements are toxic for the human body, Y has a relatively low toxicity and can be used in the medical treatment of patients [15,16]. The maximum solubility of Y in Mg is 12.5 wt % at 566 °C and decreases to 2.7 wt % at 200 °C.…”

Section: Introductionmentioning

confidence: 94%

Microhardness and In Vitro Corrosion of Heat-Treated Mg–Y–Ag Biodegradable Alloy

et al. 2017

View full text Add to dashboard Cite

Magnesium alloys are promising candidates for biodegradable medical implants which reduce the necessity of second surgery to remove the implants. Yttrium in solid solution is an attractive alloying element because it improves mechanical properties and exhibits suitable corrosion properties. Silver was shown to have an antibacterial effect and can also enhance the mechanical properties of magnesium alloys. Measurements of microhardness and electrical resistivity were used to study the response of Mg–4Y and Mg–4Y–1Ag alloys to isochronal or isothermal heat treatments. Hardening response and electrical resistivity annealing curves in these alloys were compared in order to investigate the effect of silver addition. Procedures for solid solution annealing and artificial aging of the Mg–4Y–1Ag alloy were developed. The corrosion rate of the as-cast and heat-treated Mg–4Y–1Ag alloy was measured by the mass loss method. It was found out that solid solution heat treatment, as well artificial aging to peak hardness, lead to substantial improvement in the corrosion properties of the Mg–4Y–1Ag alloy.

show abstract

“…TARE is safe [98], also compared to conventional Sorafenib treatment, and no particular attention should be paid in beta-thalassemia patients. Usually, after the procedure, oral amoxicillin/clavulanic acid (375 mg 3 times per day) and pantoprazole (40 mg per day) are administered for 3 days [99].…”

Section: Mrimentioning

confidence: 99%

Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence

et al. 2020

View full text Add to dashboard Cite

Beta-thalassemia represents a heterogeneous group of haemoglobin inherited disorders, among the most common genetic diseases in the world, frequent in the Mediterranean basin. As beta-thalassemia patients' survival has increased over time, previously unknown complications are observed with increasing frequency. Among them, an increased risk of hepatocellular carcinoma (HCC) has been registered. Our aim is to reduce inequalities in diagnosis and treatment and to offer patients univocal recommendations in any institution. The members of the panel-gastroenterologists, radiologists, surgeons and oncologists-were selected on the basis of their publication records and expertise. Thirteen clinical questions, derived from clinical needs, and an integration of all the committee members' suggestions, were formulated. Modified Delphi approach involving a detailed literature review and the collective judgement of experts, was applied to this work. Thirteen statements were derived from expert opinions' based on the current literature, on recently developed reviews and on technological advancements. Each statement is discussed in a short paragraph reporting the current key evidence. As this is an emerging issue, the number of papers on HCC in beta-thalassemia patients is limited and based on anecdotal cases rather than on randomized controlled studies. Therefore, the panel has discussed, step by step, the possible differences between beta-thalassemia and non beta-thalassemia patients. Despite the paucity of the literature, practical and concise statements were generated. This paper offers a practical guide organized by statements describing how to manage HCC in patients with betathalassemia.

show abstract

Treatment of Primary Liver Tumors with Yttrium-90 Microspheres (TheraSphere®) in High Risk Patients: Analysis of Survival and Toxicities

Cited by 11 publications

References 13 publications

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses

Microhardness and In Vitro Corrosion of Heat-Treated Mg–Y–Ag Biodegradable Alloy

Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence

Contact Info

Product

Resources

About